HC Wainwright Initiates Coverage on Medivir AB (publ) (OTCMKTS:MVRBF)

Equities researchers at HC Wainwright began coverage on shares of Medivir AB (publ) (OTCMKTS:MVRBF) in a report released on Tuesday, The Fly reports. The brokerage set a “buy” rating on the stock.

Shares of MVRBF stock opened at $2.00 on Tuesday.

Medivir AB (publ) Company Profile

Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology. The company markets Xerclear for use in the treatment of labial herpes under the Zoviduo name. It develops Remetinostat, which has completed phase II clinical trial for treating cutaneous T-cell lymphoma, as well as in phase II clinical trial for treating basal cell carcinoma; and Birinapant that is in phase II clinical trial for treating colorectal cancer.

Further Reading: The mechanics of the bid-ask spread in trading

The Fly

Receive News & Ratings for Medivir AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medivir AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.